Format

Send to

Choose Destination
Mol Cancer. 2018 Jan 27;17(1):15. doi: 10.1186/s12943-018-0772-6.

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients.

Author information

1
Lung Cancer Center, Konkuk University Medical Center, Seoul, Republic of Korea.
2
Department of Pathology, Konkuk University Medical Center, Seoul, Republic of Korea.
3
Department of Pulmonary Medicine, Konkuk University School of Medicine, 120-1 Hwayang-dong, Gwangjin-Gu, Seoul, 05030, Republic of Korea.
4
Department of Pulmonary and Critical Care Medicine, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
5
Department of Oncology, University of Ulsan, College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
6
Department of Convergence Medicine, University of Ulsan, College of Medicine & Asan Institute for Life Sciences, Asan Medical Center, Seoul, Republic of Korea.
7
Lung Cancer Center, Konkuk University Medical Center, Seoul, Republic of Korea. kyleemd@kuh.ac.kr.
8
Department of Pulmonary Medicine, Konkuk University School of Medicine, 120-1 Hwayang-dong, Gwangjin-Gu, Seoul, 05030, Republic of Korea. kyleemd@kuh.ac.kr.

Abstract

Tumor cells shed an abundance of extracellular vesicles (EVs) to body fluids containing bioactive molecules including DNA, RNA, and protein. Investigations in the field of tumor-derived EVs open a new horizon in understanding cancer biology and its potential as cancer biomarkers as well as platforms for personalized medicine. This study demonstrates that successfully isolated EVs from plasma and bronchoalveolar lavage fluid (BALF) of non-small cell lung cancer (NSCLC) patients contain DNA that can be used for EGFR genotyping through liquid biopsy. In both plasma and BALF samples, liquid biopsy results using EV DNA show higher accordance with conventional tissue biopsy compared to the liquid biopsy of cfDNA. Especially, liquid biopsy with BALF EV DNA is tissue-specific and extremely sensitive compared to using cfDNA. Furthermore, use of BALF EV DNA also demonstrates higher efficiency in comparison to tissue rebiopsy for detecting p.T790 M mutation in the patients who developed resistance to EGFR-TKIs. These finding demonstrate possibility of liquid biopsy using EV DNA potentially replacing the current diagnostic methods for more accurate, cheaper, and faster results.

KEYWORDS:

Bronchoalveolar lavage fluid; EGFR mutant DNA; Extracellular vesicles; Liquid biopsy; Non-small cell lung cancer

PMID:
29374476
PMCID:
PMC5787306
DOI:
10.1186/s12943-018-0772-6
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for BioMed Central Icon for PubMed Central
Loading ...
Support Center